Clinical trial · Observational

Evaluate EGFR Mutation Status and Impact Factors in North China

A Retrospective Study on Real-world EGFR Mutation Testing Practice Status and Impact Factors in Patients With Advanced NSCLC in North China

NCT02620657CI-TRIAL-00039860completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Approximately 3000 advanced NSCLC patients, who fulfil the inclusion/exclusion criteria, will be recruited by 30 sites in North China.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Non-Small Cell Lung Cancer	Lung Non-Small Cell Carcinoma	ALIAS	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Non interventional study	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

label
Non interventional study
description
The patients with advanced NSCLC who have the medical records from Jan 1st 2014 to Dec 31st 2014 will be recruited .
interventionNames
1. Other: Non interventional study

Primary outcomes (1)

measure
To investigate the proportion of advanced NSCLC patients who performed EGFR mutation test
timeFrame
2014.01.01-2014.12.31

Eligibility

Eligibility (as posted)

Sex: All

Show eligibility criteria text

Inclusion Criteria:

* Histological or cytological confirmed NSCLC;
* Patients were diagnosed with advanced NSCLC from Jan 1st 2014 to Dec 31st 2014;
* Researchers should collect the records of consecutive NSCLC patients in each site.

Exclusion Criteria:

* Any patients without NSCLC diagnosis;
* Any patients which were diagnosed with advanced NSCLC before Jan 1st 2014 or after Dec 31st 2014.

References

Publications (0)

Data not yet available

No reference posted for this study.